AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6338721 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast stimulation
Number of subjects: 0
Study 6338721 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 30365254 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAS+TAP
Number of subjects: 101
Study 30365254 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP
Number of subjects: 101
Study 30365254 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 101
Study 27059469 — intervention group
Group type: EXPERIMENTAL
Intervention: In-bed leg cycling (30 minutes, 5 days per week, for up to 28 days) in addition to routine physiotherapy
Number of subjects: 60
Study 27059469 — intervention group
Group type: COMPARATOR
Intervention: Routine physiotherapy alone
Number of subjects: 60
Study 26261114 — intervention group
Group type: EXPERIMENTAL
Intervention: Active learning modules (case scenarios, critical appraisal of prescriptions, drug identification)
Number of subjects: 90
Study 26261114 — intervention group
Group type: COMPARATOR
Intervention: Conventional tutorial mode
Number of subjects: 90
Study 26261114 — intervention group
Group type: EXPERIMENTAL
Intervention: Active learning sessions
Number of subjects: 90
Study 26261114 — intervention group
Group type: COMPARATOR
Intervention: Tutorial group
Number of subjects: 90
Study 26261114 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall preference
Number of subjects: 90
Study 23651425 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular testosterone undecanoate (1000 mg)
Number of subjects: 120
Study 23651425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 21908265 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk estimates with no decimal places
Number of subjects: 3422
Study 21908265 — intervention group
Group type: COMPARATOR
Intervention: Risk estimates with decimal places (1, 2, 3 decimals)
Number of subjects: 3422
Study 21908265 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk estimates with zero decimals
Number of subjects: 3422
Study 21908265 — intervention group
Group type: COMPARATOR
Intervention: One decimal place
Number of subjects: 3422
Study 21908265 — intervention group
Group type: COMPARATOR
Intervention: Two decimal places
Number of subjects: 3422
Study 21908265 — intervention group
Group type: COMPARATOR
Intervention: Three decimal places
Number of subjects: 3422
Study 18979716 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers
Number of subjects: 0
Study 18979716 — intervention group
Group type: EXPERIMENTAL
Intervention: New therapies under preclinical investigation or early stage clinical trials
Number of subjects: 0
Study 16554579 — intervention group
Group type: EXPERIMENTAL
Intervention: Mangafodipir trisodium-enhanced MRI
Number of subjects: 41
Study 16554579 — intervention group
Group type: COMPARATOR
Intervention: Ferucarbotran-enhanced MRI
Number of subjects: 41
Study 14570682 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume breathing after maximal exhalation
Number of subjects: 23
Study 14570682 — intervention group
Group type: COMPARATOR
Intervention: Tidal volume breathing alone
Number of subjects: 23
Study 10764418 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy humans (n=11)
Number of subjects: 22
Study 10764418 — intervention group
Group type: COMPARATOR
Intervention: CHF patients (n=11)
Number of subjects: 22
Study 10764418 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine (10 micromol/L) exposure in isolated cardiomyocytes
Number of subjects: 22
Study 8650928 — intervention group
Group type: EXPERIMENTAL
Intervention: Wobenzym (enzyme therapy)
Number of subjects: 29
Study 8650928 — intervention group
Group type: COMPARATOR
Intervention: Lynestrenol (hormone therapy)
Number of subjects: 29
Study 1611639 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 180 mg, 360 mg, and 540 mg once daily for two weeks
Number of subjects: 107
Study 1611639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 6146045 — intervention group
Group type: EXPERIMENTAL
Intervention: 200,000 IU of vitamin A given once every 6 months
Number of subjects: 50000
Study 6146045 — intervention group
Group type: COMPARATOR
Intervention: Control areas (no vitamin A supplementation)
Number of subjects: 50000
Study 6146045 — intervention group
Group type: COMPARATOR
Intervention: Children not receiving vitamin A supplements (case-control analysis)
Number of subjects: 50000
Study 30082107 — intervention group
Group type: EXPERIMENTAL
Intervention: Variably Occluded Face Mask (VOFM)
Number of subjects: 0
Study 29356207 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive mexiletine therapy
Number of subjects: 259
Study 29356207 — intervention group
Group type: COMPARATOR
Intervention: Catheter ablation
Number of subjects: 259
Study 27021829 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent involvement intervention (weekly newsletters and text messages for 5 weeks)
Number of subjects: 42
Study 27021829 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 42
Study 24060708 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive interdisciplinary pain treatment (IIPT)
Number of subjects: 104
Study 24060708 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group (WCG)
Number of subjects: 104
Study 22488252 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-supplemented milk (200 ml with 5 mg F/l as NaF once a day)
Number of subjects: 0
Study 22488252 — intervention group
Group type: COMPARATOR
Intervention: Unsupplemented milk (200 ml)
Number of subjects: 0
Study 22488252 — intervention group
Group type: COMPARATOR
Intervention: No milk consumption
Number of subjects: 0
Study 20884063 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR 150mg/day
Number of subjects: 919
Study 20884063 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR 300mg/day
Number of subjects: 919
Study 20884063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 919
Study 18633021 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 0.075 mg
Number of subjects: 544
Study 18633021 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 0.025 mg
Number of subjects: 544
Study 18633021 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 0.050 mg
Number of subjects: 544
Study 18633021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 544
Study 16822125 — intervention group
Group type: EXPERIMENTAL
Intervention: Invariant approach
Number of subjects: 0
Study 16822125 — intervention group
Group type: EXPERIMENTAL
Intervention: Heuristic approach
Number of subjects: 0
Study 16822125 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemplar-based approach
Number of subjects: 0
Study 16822125 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple strategies
Number of subjects: 0
Study 12819656 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) in the upright position
Number of subjects: 53
Study 12819656 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine (Ach) in the upright position
Number of subjects: 53
Study 11027904 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone 2 mg
Number of subjects: 60
Study 11027904 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 10 mg
Number of subjects: 60
Study 11027904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 8676034 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened postoperative mobilization programme (full activity allowed after 8 weeks)
Number of subjects: 82
Study 8676034 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative mobilization programme (unrestricted use not allowed until 10 weeks)
Number of subjects: 82
Study 2066455 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose fluoxetine (median 80 mg/day)
Number of subjects: 706
Study 2066455 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose imipramine (median 200 mg/day)
Number of subjects: 706
Study 2066455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 706
Study 6190888 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metronidazole alone
Number of subjects: 100
Study 6190888 — intervention group
Group type: COMPARATOR
Intervention: Combination of metronidazole and gentamicin
Number of subjects: 100
Study 6190888 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of bowel preparation (poor)
Number of subjects: 100
Study 29505321 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Exercise Program (HEP) consisting of three static balance exercises: feet-together, single-leg stance, and tandem, performed twice for 30-60 seconds, once per day, 3 days per week for 12 weeks.
Number of subjects: 6
Study 29505321 — intervention group
Group type: COMPARATOR
Intervention: No Home Exercise Program (No HEP)
Number of subjects: 6
Study 29505321 — intervention group
Group type: COMPARATOR
Intervention: Healthy Control Group (HCG)
Number of subjects: 6
Study 30138021 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-based physical activity intervention (4 videoconference sessions including training in communication and support skills and behavior change techniques)
Number of subjects: 20
Study 30138021 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 20
Study 24832388 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 μg/kg fentanyl (group F)
Number of subjects: 66
Study 24832388 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 μg/kg dexmedetomidine (group D0.5)
Number of subjects: 66
Study 24832388 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 μg/kg dexmedetomidine (group D1.0)
Number of subjects: 66
Study 24185044 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir + Tenofovir/Emtricitabine + Maraviroc (MVC), n=15
Number of subjects: 30
Study 24185044 — intervention group
Group type: COMPARATOR
Intervention: Raltegravir + Tenofovir/Emtricitabine (Control), n=15
Number of subjects: 30
Study 22260359 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-dosed participants
Number of subjects: 101
Study 22260359 — intervention group
Group type: COMPARATOR
Intervention: Placebo (non-alcoholic drink)
Number of subjects: 101
Study 22260359 — intervention group
Group type: COMPARATOR
Intervention: Control (diluted orange cordial)
Number of subjects: 101
Study 22260359 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-dosed females
Number of subjects: 101
Study 22260359 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 101
Study 20437859 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course radiation plus adjuvant temozolomide (150-200 mg/m² for 5 days every 28-day cycle)
Number of subjects: 45
Study 20437859 — intervention group
Group type: COMPARATOR
Intervention: Short-course radiation (30 Gy in 6 fractions over 2 weeks)
Number of subjects: 45
Study 17504798 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 142
Study 17504798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 16248466 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast velocity isokinetic eccentric contractions (FST, 3.14 rad x s(‐1))
Number of subjects: 15
Study 16248466 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow velocity isokinetic eccentric contractions (SLW, 0.52 rad x s(‐1))
Number of subjects: 15
Study 12664519 — intervention group
Group type: EXPERIMENTAL
Intervention: ALP (Alkaline Phosphatase)
Number of subjects: 60
Study 12664519 — intervention group
Group type: EXPERIMENTAL
Intervention: LDH (Lactate Dehydrogenase)
Number of subjects: 60
Study 12664519 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple bone lesions (> 8)
Number of subjects: 60
Study 12664519 — intervention group
Group type: EXPERIMENTAL
Intervention: Painful metastases (more than 7 in the VAS)
Number of subjects: 60
Study 12664519 — intervention group
Group type: EXPERIMENTAL
Intervention: Median survival
Number of subjects: 60
Study 9513589 — intervention group
Group type: EXPERIMENTAL
Intervention: 23 valent pneumococcal vaccine
Number of subjects: 66
Study 7608314 — intervention group
Group type: EXPERIMENTAL
Intervention: GITS (240 mg)
Number of subjects: 24
Study 7608314 — intervention group
Group type: EXPERIMENTAL
Intervention: GITS (120 mg)
Number of subjects: 24
Study 7608314 — intervention group
Group type: COMPARATOR
Intervention: PeHCl solution (given every 6 hours)
Number of subjects: 24
Study 7608314 — intervention group
Group type: COMPARATOR
Intervention: Timed-release 12-hour pseudoephedrine capsule (given every 12 hours)
Number of subjects: 24
Study 7608314 — intervention group
Group type: EXPERIMENTAL
Intervention: GITS with high-fat breakfast
Number of subjects: 24
Study 7608314 — intervention group
Group type: EXPERIMENTAL
Intervention: GITS without high-fat breakfast
Number of subjects: 24
Study 2364843 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard nicardipine (20 mg)
Number of subjects: 42
Study 2364843 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release nicardipine (30 mg twice a day)
Number of subjects: 42
Study 2364843 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations of nicardipine
Number of subjects: 42
Study 369991 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer factor (TF)
Number of subjects: 4
Study 31215037 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 64231
Study 30920602 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic and resistance exercise intervention (supervised sessions thrice weekly for 16 weeks)
Number of subjects: 100
Study 30920602 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study 27943372 — intervention group
Group type: EXPERIMENTAL
Intervention: Error Management Training (EMT)
Number of subjects: 60
Study 27943372 — intervention group
Group type: COMPARATOR
Intervention: Error Avoidance Training (EAT)
Number of subjects: 60
Study 26881502 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraclavicular radiation therapy (SC‐RT)
Number of subjects: 40
Study 26881502 — intervention group
Group type: COMPARATOR
Intervention: Control group (adjuvant chest wall/breast RT only)
Number of subjects: 40
Study 23668671 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI genetic risk score (GRS)
Number of subjects: 459
Study 23668671 — intervention group
Group type: EXPERIMENTAL
Intervention: WHR genetic risk score (GRS)
Number of subjects: 459
Study 23668671 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet low in fibre
Number of subjects: 459
Study 23668671 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle modification
Number of subjects: 459
Study 21044897 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy in low RVP (≤ 50%)
Number of subjects: 1057
Study 21044897 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy in high RVP (> 50%)
Number of subjects: 1057
Study 21044897 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy in low RVP (≤ 50%) during late phase
Number of subjects: 1057
Study 21044897 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy in high RVP (> 50%) during late phase
Number of subjects: 1057
Study 21044897 — intervention group
Group type: COMPARATOR
Intervention: High RVP (> 50%) vs Low RVP (≤ 50%) in non-LBBB patients
Number of subjects: 1057
Study 18675542 — intervention group
Group type: EXPERIMENTAL
Intervention: Low alcohol beer (3.8%)
Number of subjects: 34
Study 18675542 — intervention group
Group type: COMPARATOR
Intervention: Regular strength beer (5.3%)
Number of subjects: 34
Study 17204591 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypobaric hypoxia (simulated altitude of 4,000-5,500 m)
Number of subjects: 22
Study 17204591 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (500 m)
Number of subjects: 22
Study 15548326 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-carried ultrasound (HCU)
Number of subjects: 44
Study 15548326 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive echocardiography (CE)
Number of subjects: 44
Study 11697839 — intervention group
Group type: EXPERIMENTAL
Intervention: irinotecan 175 mg/m2 given on days 1 and 10, repeated every three weeks for a total of six courses
Number of subjects: 38
Study 9543310 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational training
Number of subjects: 148
Study 9543310 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 148
Study 8156481 — intervention group
Group type: EXPERIMENTAL
Intervention: Western R1 resection with limited N1-level lymphadenectomy
Number of subjects: 389
Study 8156481 — intervention group
Group type: COMPARATOR
Intervention: Japanese R2 resection with extended lymphadenectomy including N2-level
Number of subjects: 389
Study 3408037 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg nicergoline
Number of subjects: 20
Study 3408037 — intervention group
Group type: COMPARATOR
Intervention: 10 ml saline
Number of subjects: 20
Study 31710104 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg (with 240 mg loading dose)
Number of subjects: 1773
Study 31710104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1773
Study 30615554 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics fibrosis index (RFI)
Number of subjects: 436
Study 30615554 — intervention group
Group type: COMPARATOR
Intervention: Normalized liver enhancement
Number of subjects: 436
Study 30615554 — intervention group
Group type: COMPARATOR
Intervention: Aspartate transaminase-to-platelet ratio index (APRI)
Number of subjects: 436
Study 30615554 — intervention group
Group type: COMPARATOR
Intervention: Fibrosis-4 index
Number of subjects: 436
Study 30615554 — intervention group
Group type: EXPERIMENTAL
Intervention: RFI for diagnosing stage F2-F4
Number of subjects: 436
Study 30615554 — intervention group
Group type: EXPERIMENTAL
Intervention: RFI for diagnosing stage F3-F4
Number of subjects: 436
Study 30615554 — intervention group
Group type: EXPERIMENTAL
Intervention: RFI for diagnosing stage F4
Number of subjects: 436
Study 28868630 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-based conditional power assessment
Number of subjects: 0
Study 26259632 — intervention group
Group type: EXPERIMENTAL
Intervention: Barley kernel-based bread (BB)
Number of subjects: 20
Study 26259632 — intervention group
Group type: COMPARATOR
Intervention: Reference white wheat bread
Number of subjects: 20
Study 23882169 — intervention group
Group type: EXPERIMENTAL
Intervention: Active implementation model for chronic disease management program for COPD
Number of subjects: 0
Study 23882169 — intervention group
Group type: COMPARATOR
Intervention: Usual implementation model
Number of subjects: 0
Study 21722959 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ketamine (K2: 10 mg and 25 mg doses at 11 and 4 hours preoperatively)
Number of subjects: 120
Study 21722959 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ketamine (K3: 5 mg, 10 mg, and 25 mg doses at 17, 11, and 4 hours preoperatively)
Number of subjects: 120
Study 21722959 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline) for K2 (P2)
Number of subjects: 120
Study 21722959 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline) for K3 (P3)
Number of subjects: 120
Study 21722959 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-ketamine-injection (K1: 25 mg at 4 hours preoperatively)
Number of subjects: 120
Study 19155978 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL) conversion
Number of subjects: 830
Study 19155978 — intervention group
Group type: COMPARATOR
Intervention: Calcineurin inhibitors (CNI) continuation
Number of subjects: 830
Study 16467647 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored dietary education to encourage a decrease in sodium intake and an increase in the intake of vitamin C and carotene, and of fruit and vegetables
Number of subjects: 550
Study 16467647 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary intervention)
Number of subjects: 550
Study 16467647 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored dietary education
Number of subjects: 550
Study 14732749 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients undergoing PCI
Number of subjects: 2694
Study 14732749 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic patients undergoing PCI
Number of subjects: 2694
Study 11407442 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted maintenance pharmacotherapy
Number of subjects: 85
Study 11407442 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose maintenance neuroleptic treatment
Number of subjects: 85
Study 11407442 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Targeted and Standard-dose)
Number of subjects: 85
Study 8986684 — intervention group
Group type: EXPERIMENTAL
Intervention: E1S (estrone sulfate) 0.625 mg
Number of subjects: 8
Study 8986684 — intervention group
Group type: EXPERIMENTAL
Intervention: EqS (equilin sulfate) 0.3 mg
Number of subjects: 8
Study 8986684 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 alpha-ES (17 alpha-dihydroequilin sulfate) 0.2 mg
Number of subjects: 8
Study 8275614 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 12
Study 8275614 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 12
Study 8275614 — intervention group
Group type: EXPERIMENTAL
Intervention: Naringin capsule
Number of subjects: 12
Study 2886340 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers (BB)
Number of subjects: 60
Study 2886340 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers + Chlorthalidone (BB + CTD)
Number of subjects: 60
Study 2886340 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone (CTD)
Number of subjects: 60
Study 28737273 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG after ACS
Number of subjects: 3054
Study 28737273 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger, male subjects without metabolic syndrome and no history of chronic obstructive pulmonary disease, renal insufficiency, atrial fibrillation, or heart failure
Number of subjects: 3054
Study 26922669 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic cartilage implant
Number of subjects: 202
Study 26922669 — intervention group
Group type: COMPARATOR
Intervention: Arthrodesis
Number of subjects: 202
Study 25363178 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg daily
Number of subjects: 96